| Host |
Mouse |
| Clone |
YP7 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Thyroid carcinoma |
| Dilution |
- |
| Isotype |
IgG1 kappa |
| Localization |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
6 ml |
Ready-to-use |
CE/IVD |
PDM561 |
-
|
| Host |
Mouse |
| Clone |
YP7 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Thyroid carcinoma |
| Dilution |
- |
| Isotype |
IgG1 kappa |
| Localization |
Cytoplasm |
Glypican-3
|
Diagnostic Biosystems |
YP7 |
25 ml |
Ready-to-use |
CE/IVD |
PDM561-25 |
-
|
| Host |
Mouse |
| Clone |
1G12 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
1ml |
Concentrate |
CE/IVD |
Z2103ML |
-
|
| Host |
Mouse |
| Clone |
1G12 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
7 ml |
Ready-to-use |
CE/IVD |
Z2103MP |
-
|
| Host |
Mouse |
| Clone |
1G12 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
0.5 ml |
Concentrate |
CE/IVD |
Z2103MS |
-
|
| Host |
Mouse |
| Clone |
1G12 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
A fragment containing the last 70 amino acids of the core glypican-3 protein |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
1G12 |
0.1 ml |
Concentrate |
CE/IVD |
Z2103MT |
-
|
| Host |
Mouse |
| Clone |
ZM138 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human GPC3 protein fragment |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
1.0 ml |
Concentrate |
CE/IVD |
Z2449ML |
-
|
| Host |
Mouse |
| Clone |
ZM138 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human GPC3 protein fragment |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
7 ml |
Ready-to-use |
CE/IVD |
Z2449MP |
-
|
| Host |
Mouse |
| Clone |
ZM138 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human GPC3 protein fragment |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
0.5 ml |
Concentrate |
CE/IVD |
Z2449MS |
-
|
| Host |
Mouse |
| Clone |
ZM138 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatocellular carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant human GPC3 protein fragment |
| Localization |
Cytoplasm and Cell membrane |
Glypican 3
|
Zeta Corporation |
ZM138 |
0.1 ml |
Concentrate |
CE/IVD |
Z2449MT |
-
|
| Host |
Goat |
| Clone |
polyclonal |
| Format |
Purified |
| Method |
F, EL, WB |
| Isotype |
Goat IgG |
| Immunogen |
Purified canine IgA |
Goat anti-Dog IgA
|
Zytomed Systems GmbH |
polyclonal |
1 mg |
Purified |
RUO |
609-0032 |
-
|
| Host |
Rat |
| Clone |
RB6-8C5 |
| Format |
Purified |
| Method |
F, WB, IP, FL |
| Isotype |
Rat IgG2b |
| Immunogen |
Normal murine bone marrow cells |
Gr-1
|
Zytomed Systems GmbH |
RB6-8C5 |
250 µg |
Purified |
RUO |
607-0168 |
-
|
| Host |
Mouse |
| Clone |
HIS48 |
| Format |
TCS |
| Method |
F, FL |
| Isotype |
Mouse IgM |
| Immunogen |
PVG rat spleen cell suspension |
Granulocytes & Erythroid Cells
|
Zytomed Systems GmbH |
HIS48 |
2 ml |
TCS |
RUO |
607-0199 |
-
|
| Host |
Mouse |
| Clone |
GB7 |
| Format |
Purified |
| Method |
WB, P |
| Pretreatment |
Citrate |
| Dilution |
1:50 - 1:200 (P) |
| Isotype |
Mouse IgG2a |
| Immunogen |
Recombinant Granzyme B |
Granzyme B
|
Zytomed Systems GmbH |
GB7 |
100 µg |
Purified |
RUO |
607-0205 |
-
|
| Host |
Mouse |
| Clone |
11F1 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Spleen or tonsil |
| Dilution |
1:50 |
| Isotype |
IgG2a |
| Immunogen |
Recombinant protein corresponding to the Nterminus of granzyme B |
| Localization |
Cytoplasmic lytic granules |
Granzyme B
|
Biocare Medical |
11F1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3202A |
-
|
| Host |
Mouse |
| Clone |
11F1 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Spleen or tonsil |
| Dilution |
1:50 |
| Isotype |
IgG2a |
| Immunogen |
Recombinant protein corresponding to the Nterminus of granzyme B |
| Localization |
Cytoplasmic lytic granules |
Granzyme B
|
Biocare Medical |
11F1 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3202B |
-
|
| Host |
Mouse |
| Clone |
11F1 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Spleen or tonsil |
| Dilution |
- |
| Isotype |
IgG2a |
| Immunogen |
Recombinant protein corresponding to the Nterminus of granzyme B |
| Localization |
Cytoplasmic lytic granules |
Granzyme B
|
Biocare Medical |
11F1 |
6 ml |
Ready-to-use |
CE/IVD |
API3202AA |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Hodgkin´s Lymphoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR050 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Hodgkin´s Lymphoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP105 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Hodgkin´s Lymphoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP105-01 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Hodgkin´s Lymphoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Granular Cytoplasmic |
Granzyme B
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP105-05 |
-
|
| Host |
Mouse |
| Clone |
ZM66 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Tonsil. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human GZMB protein fragment (around aa 73-187) |
| Localization |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
1.0 ml |
Concentrate |
CE/IVD |
Z2376ML |
-
|
| Host |
Mouse |
| Clone |
ZM66 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Tonsil. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human GZMB protein fragment (around aa 73-187) |
| Localization |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
7 ml |
Ready-to-use |
CE/IVD |
Z2376MP |
-
|
| Host |
Mouse |
| Clone |
ZM66 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Tonsil. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human GZMB protein fragment (around aa 73-187) |
| Localization |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
0.5 ml |
Concentrate |
CE/IVD |
Z2376MS |
-
|
| Host |
Mouse |
| Clone |
ZM66 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Tonsil. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
Recombinant human GZMB protein fragment (around aa 73-187) |
| Localization |
Granular Cytoplasm |
Granzyme B
|
Zeta Corporation |
ZM66 |
0.1 ml |
Concentrate |
CE/IVD |
Z2376MT |
-
|
| Host |
Mouse |
| Clone |
ZM140 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pituitary. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
| Localization |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
1 ml |
Concentrate |
CE/IVD |
Z2451ML |
-
|
| Host |
Mouse |
| Clone |
ZM140 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pituitary. |
| Dilution |
- |
| Isotype |
IgG2b /κ |
| Immunogen |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
| Localization |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
7 ml |
Ready-to-use |
CE/IVD |
Z2451MP |
-
|
| Host |
Mouse |
| Clone |
ZM140 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pituitary. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
| Localization |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
0.5 ml |
Concentrate |
CE/IVD |
Z2451MS |
-
|
| Host |
Mouse |
| Clone |
ZM140 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Pituitary. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG2b /κ |
| Immunogen |
A recombinant human Growth Hormone (GH) fragment (aa58-187) |
| Localization |
Cytoplasm |
Growth Hormone
|
Zeta Corporation |
ZM140 |
0.1 ml |
Concentrate |
CE/IVD |
Z2451MT |
-
|
| Host |
Rabbit |
| Clone |
C36B11 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Diva modified Citrate |
| Positive control |
Ovarian cancer |
| Dilution |
1:100 |
| Isotype |
IgG |
| Localization |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3249A |
-
|
| Host |
Rabbit |
| Clone |
C36B11 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Diva modified Citrate |
| Positive control |
Ovarian cancer |
| Dilution |
1:100 |
| Isotype |
IgG |
| Localization |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
1 ml |
Concentrate |
CE/IVD |
ACI3249C |
-
|
| Host |
Rabbit |
| Clone |
C36B11 |
| Format |
Ready-to-use |
| Method |
P |
| Positive control |
Ovarian cancer |
| Dilution |
- |
| Isotype |
IgG |
| Localization |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3249G7 |
-
|
| Host |
Rabbit |
| Clone |
C36B11 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Diva modified Citrate |
| Positive control |
Ovarian cancer |
| Dilution |
- |
| Isotype |
IgG |
| Localization |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
6 ml |
Ready-to-use |
CE/IVD |
API3249AA |
-
|
| Host |
Rabbit |
| Clone |
C36B11 |
| Format |
Ready-to-use |
| Method |
P |
| Positive control |
Ovarian cancer |
| Dilution |
- |
| Isotype |
IgG |
| Localization |
Nucleus |
H3K27me3 [C36B11]
|
Biocare Medical |
C36B11 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3249G |
-
|
| Host |
Mouse |
| Clone |
DBA.44 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:15 - 1:30 |
| Isotype |
Mouse IgM |
| Localization |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
1 ml |
Concentrate |
CE/IVD |
MOB200 |
-
|
| Host |
Mouse |
| Clone |
DBA.44 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:15 - 1:30 |
| Isotype |
Mouse IgM |
| Localization |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
0.1 ml |
Concentrate |
CE/IVD |
MOB200-01 |
-
|
| Host |
Mouse |
| Clone |
DBA.44 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:15 - 1:30 |
| Isotype |
Mouse IgM |
| Localization |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
0.5 ml |
Concentrate |
CE/IVD |
MOB200-05 |
-
|
| Host |
Mouse |
| Clone |
DBA.44 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Mouse IgM |
| Localization |
Cytoplasm, Cell Membrane |
Hairy Cell Leukemia
|
Diagnostic Biosystems |
DBA.44 |
6 ml |
Ready-to-use |
CE/IVD |
PDM024 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hepatitis B infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Hepatitis B virus |
| Localization |
Nucleus |
HBcAg
|
Zeta Corporation |
polyclonal |
1 ml |
Concentrate |
RUO |
Z2085RL-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatitis B virus infected liver |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
--- |
| Localization |
Nuclear |
HBcAg
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
RUO |
Z2085RP-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hepatitis B infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Hepatitis B virus |
| Localization |
Nucleus |
HBcAg
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
RUO |
Z2085RS-R |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Pretreatment |
Citrate or EDTA |
| Positive control |
Hepatitis B infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Hepatitis B virus |
| Localization |
Nucleus |
HBcAg
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
RUO |
Z2085RT-R |
-
|
| Host |
Rabbit |
| Clone |
ZR393 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatitis B virus infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
--- |
| Localization |
Nuclear |
HBsAg
|
Zeta Corporation |
ZR393 |
1 ml |
Concentrate |
RUO |
Z2749RL-R |
-
|
| Host |
Rabbit |
| Clone |
ZR393 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatitis B virus infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
--- |
| Localization |
Nuclear |
HBsAg
|
Zeta Corporation |
ZR393 |
7 ml |
Concentrate |
RUO |
Z2749RP-R |
-
|
| Host |
Rabbit |
| Clone |
ZR393 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatitis B virus infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
--- |
| Localization |
Nuclear |
HBsAg
|
Zeta Corporation |
ZR393 |
0.5 ml |
Concentrate |
RUO |
Z2749RS-R |
-
|
| Host |
Rabbit |
| Clone |
ZR393 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Hepatitis B virus infected liver |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
--- |
| Localization |
Nuclear |
HBsAg
|
Zeta Corporation |
ZR393 |
0.1 ml |
Concentrate |
RUO |
Z2749RT-R |
-
|
| Host |
Rabbit |
| Clone |
ZR362 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Placenta or choriocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human CGB protein |
| Localization |
Cytoplasm |
HCG
|
Zeta Corporation |
ZR362 |
1 ml |
Concentrate |
CE/IVD |
Z2738RL |
-
|
| Host |
Rabbit |
| Clone |
ZR362 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Placenta or choriocarcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human CGB protein |
| Localization |
Cytoplasm |
HCG
|
Zeta Corporation |
ZR362 |
7 ml |
Concentrate |
CE/IVD |
Z2738RP |
-
|
| Host |
Rabbit |
| Clone |
ZR362 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Placenta or choriocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human CGB protein |
| Localization |
Cytoplasm |
HCG
|
Zeta Corporation |
ZR362 |
0.5 ml |
Concentrate |
CE/IVD |
Z2738RS |
-
|
| Host |
Rabbit |
| Clone |
ZR362 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Placenta or choriocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant full-length human CGB protein |
| Localization |
Cytoplasm |
HCG
|
Zeta Corporation |
ZR362 |
1 ml |
Concentrate |
CE/IVD |
Z2738RT |
-
|